BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 12465154)

  • 1. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
    Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
    Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
    Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
    Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations].
    De Bandt M; Goycochea MV; Meyer O; Delahousse M; Palazzo E; M'Bappé P; Kahn MF
    Ann Med Interne (Paris); 1994; 145(2):75-87. PubMed ID: 8024184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC; Wong RW; Lau CS
    Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K; Wildt L; Kalden JR; Manger B
    Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
    Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.
    Baca V; Lavalle C; García R; Catalán T; Sauceda JM; Sánchez G; Martínez I; Ramírez ML; Márquez LM; Rojas JC
    J Rheumatol; 1999 Feb; 26(2):432-9. PubMed ID: 9972981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study.
    Baba S; Katsumata Y; Kawaguchi Y; Gono T; Sugiura T; Kanno T; Hara M; Yamanaka H
    BMC Womens Health; 2011 Jun; 11():28. PubMed ID: 21663683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone.
    Lawrenz B; Henes J; Henes M; Neunhoeffer E; Schmalzing M; Fehm T; Kïtter I
    Lupus; 2011 Oct; 20(11):1193-7. PubMed ID: 21768179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.
    Boumpas DT; Austin HA; Vaughan EM; Yarboro CH; Klippel JH; Balow JE
    Ann Intern Med; 1993 Sep; 119(5):366-9. PubMed ID: 8338289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs.
    Ramsey-Goldman R; Mientus JM; Kutzer JE; Mulvihill JJ; Medsger TA
    J Rheumatol; 1993 Jul; 20(7):1152-7. PubMed ID: 8371208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pneumatosis cystoides intestinalis associated with intravenous pulse cyclophosphamide treatment for systemic lupus erythematosus].
    Nonaka D; Higuchi M; Yoshizawa S; Horiuchi T; Nakashima H; Niho Y
    Ryumachi; 1998 Aug; 38(4):605-10. PubMed ID: 9785989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles.
    Huong DL; Wechsler B; Vauthier-Brouzes D; Duhaut P; Costedoat N; Lefebvre G; Piette JC
    Semin Arthritis Rheum; 2002 Dec; 32(3):174-88. PubMed ID: 12528082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.